Anyone who pays attention to the pharmaceutical industry is probably aware that corporate reputation has been stuck in the ‘damaged goods’ file. Chalk that up to years of controversy over safety, pricing and transparency. And the problem persists – in a big way, according to a new survey of patient groups around the world that considered 29 large drugmakers. The overall industry reputation, in fact, has taken a dive. Only 34 percent of 600 patient groups say that multinational drugmakers had an ‘excellent’ or ‘good’ reputation last year, according to Patient View, the research firm that conducted the survey. This compares with 42 percent in the 2011 survey of 500 patient groups.
